RANI

Rani TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.60

+86.5% vs current

Most likely

Base case

50%

Probability

Target price

$0.85

-0.9% vs current

B-

Bear case

25%

Probability

Target price

$0.35

-59.2% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment looks cautious rather than outright bullish. March 26, 2026 filings improved the balance-sheet narrative and confirmed real partnership economics, but the deterministic score is now neutral with low catalyst density and higher uncertainty, which fits a monitoring-style setup more than an aggressive re-rating call. The key positive facts are the Phase 1 start for RT-114, debt elimination, and runway into Q4 2027, while the key restraint is that meaningful milestone recognition and later clinical proof are still ahead [#8-K-2026-03-26][#10-K-2026-03-26].

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31catalystChugai collaboration milestone conversion is a real but still constrained upside leverHigh impact

The Chugai agreement included a $10.0 million upfront payment and eligibility for up to $18.0 million of technology-transfer milestones plus later development and sales milestones, but the 10-K said milestone-related variable consideration was not yet considered probable as of December 31, 2025, so investors should treat milestone capture as possible rather than assured [#10-K-2026-03-26].

2027-06-30catalystRunway improved, but dilution risk is deferred rather than removedHigh impact

The March 26, 2026 earnings release said cash, cash equivalents and marketable securities were $49.7 million at December 31, 2025 and should fund operations into the fourth quarter of 2027, including an expected Chugai technology-transfer milestone payment; that lowers immediate financing pressure but leaves the stock exposed if spending rises or milestone timing slips [#8-K-2026-03-26].

2027-12-31eventRT-114 Phase 1 execution remains the clearest operating inflectionHigh impact

Rani disclosed that it initiated the RT-114 Phase 1 study in December 2025 and said the next update is expected after completion of the trial in 2027, making interim execution signals important but limiting near-term readout visibility [#10-K-2026-03-26].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology